The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI) has announced an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, building upon their existing collaboration in Florida. The expanded partnership aims to enhance access to cancer clinical trials across TOI's markets.

The collaboration focuses on integrating clinical research into community oncology settings, with key benefits including:

• Increased patient access to leading-edge therapies
• Streamlined study activation and enrollment processes
• Enhanced trial performance through unified oversight
• Improved infrastructure for regulatory and operational support

TOI CEO Daniel Virnich emphasized that this expansion will help scale their research infrastructure while maintaining focus on patient care. Chief Medical Officer Yale Podnos highlighted the initiative's goal of making clinical research a routine part of patient care across all markets, with a shared commitment to advancing health equity in oncology research.

Positive

• Expansion of research capabilities across markets
• Enhanced operational efficiency through centralized support
• Improved access to clinical trials for patients
• Potential for accelerated trial enrollment and study activation

Negative

• None.

CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI’s ongoing commitment to integrating clinical research into community oncology settings.

“Expanding our research collaboration with Helios Clinical is a natural next step,” said Daniel Virnich, MD, CEO at TOI. “They’ve proven to be a highly capable partner, helping us streamline study activation, accelerate enrollment, and reduce operational burden on our sites. This move allows us to scale our research infrastructure much more quickly while staying laser-focused on patient care.”

Strategic Benefits of the Partnership:

• Expanded Access to Clinical Trials: Patients will gain greater access to leading-edge therapies through trials supported by Helios’ centralized operations and outreach model.
• Enhanced Trial Performance: Sponsors benefit from streamlined startup processes, optimized patient matching, and unified oversight.
• Scalable Infrastructure: Helios provides regulatory, recruitment, and operational support, enabling TOI’s clinicians to focus on delivering world-class care while expanding their research footprint.
• Equity in Oncology Research: Both organizations share a commitment to enrolling diverse and underrepresented patient populations, advancing health equity in oncology care.

“This isn’t just about geographic growth,” said Yale Podnos, MD, Chief Medical Officer at TOI. “It’s about ensuring that clinical research becomes a routine, integral part of patient care in every market we serve.”

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

About Helios Clinical Research
Helios Clinical Research is a full-service site network known for its integrated, tech-forward approach to clinical trial execution. With expertise in oncology and a national footprint, Helios partners with leading healthcare organizations to bring high-performing, patient-first research capabilities into real-world care settings.

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

Solebury Strategic Communications
investors@theoncologyinstitute.com

FAQ

What is the impact of TOI's expanded partnership with Helios Clinical Research?

The partnership expands access to cancer clinical trials, streamlines study processes, and enhances research infrastructure across TOI's markets while focusing on patient care and health equity.

How will TOI's collaboration with Helios Clinical benefit cancer patients?

Patients will gain greater access to leading-edge cancer therapies through clinical trials, supported by Helios' centralized operations and outreach model.

What operational improvements will TOI achieve through the Helios Clinical partnership?

TOI will benefit from streamlined startup processes, optimized patient matching, unified oversight, and enhanced regulatory and recruitment support.

How does TOI's expanded research partnership address health equity in cancer care?

The partnership focuses on enrolling diverse and underrepresented patient populations in clinical trials, advancing health equity in oncology research and care.